Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02942264
Title TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

glioblastoma

gliosarcoma

malignant astrocytoma

Therapies

Zotiraciclib

Temozolomide + Zotiraciclib

Age Groups:
Covered Countries USA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field